CA2683786C - Use of tapentadol in the treatment of pain and with a reduced incidence of tapentadol-induced side-effects - Google Patents

Use of tapentadol in the treatment of pain and with a reduced incidence of tapentadol-induced side-effects Download PDF

Info

Publication number
CA2683786C
CA2683786C CA2683786A CA2683786A CA2683786C CA 2683786 C CA2683786 C CA 2683786C CA 2683786 A CA2683786 A CA 2683786A CA 2683786 A CA2683786 A CA 2683786A CA 2683786 C CA2683786 C CA 2683786C
Authority
CA
Canada
Prior art keywords
tapentadol
pain
treatment
effects
reduced incidence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2683786A
Other languages
English (en)
French (fr)
Other versions
CA2683786A1 (en
Inventor
Claudia Lange
Ferdinand Rombout
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Gruenenthal GmbH
Original Assignee
Gruenenthal GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38123877&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CA2683786(C) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Gruenenthal GmbH filed Critical Gruenenthal GmbH
Publication of CA2683786A1 publication Critical patent/CA2683786A1/en
Application granted granted Critical
Publication of CA2683786C publication Critical patent/CA2683786C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pain & Pain Management (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Adhesive Tapes (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CA2683786A 2007-04-23 2008-04-21 Use of tapentadol in the treatment of pain and with a reduced incidence of tapentadol-induced side-effects Active CA2683786C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP07008218A EP1985292A1 (en) 2007-04-23 2007-04-23 Titration of tapentadol
EP07008218.5 2007-04-23
PCT/EP2008/003178 WO2008128740A1 (en) 2007-04-23 2008-04-21 Titration of tapentadol

Publications (2)

Publication Number Publication Date
CA2683786A1 CA2683786A1 (en) 2008-10-30
CA2683786C true CA2683786C (en) 2021-10-26

Family

ID=38123877

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2683786A Active CA2683786C (en) 2007-04-23 2008-04-21 Use of tapentadol in the treatment of pain and with a reduced incidence of tapentadol-induced side-effects

Country Status (21)

Country Link
US (4) US20090012180A1 (enExample)
EP (5) EP1985292A1 (enExample)
JP (4) JP5933176B2 (enExample)
KR (3) KR20150027840A (enExample)
CN (1) CN101730530B (enExample)
AT (1) ATE534378T1 (enExample)
AU (1) AU2008241013B2 (enExample)
CA (1) CA2683786C (enExample)
CY (1) CY1112320T1 (enExample)
DK (1) DK2148670T3 (enExample)
ES (1) ES2378255T3 (enExample)
HR (1) HRP20120147T1 (enExample)
IL (1) IL201479A (enExample)
MX (1) MX2009011444A (enExample)
NZ (1) NZ580415A (enExample)
PL (1) PL2148670T3 (enExample)
PT (1) PT2148670E (enExample)
RU (1) RU2472497C2 (enExample)
SI (1) SI2148670T1 (enExample)
WO (1) WO2008128740A1 (enExample)
ZA (1) ZA200907355B (enExample)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1985292A1 (en) 2007-04-23 2008-10-29 Grünenthal GmbH Titration of tapentadol
AU2009340504A1 (en) * 2008-10-30 2010-08-26 Grunenthal Gmbh Novel and potent tapentadol dosage forms
US8870876B2 (en) * 2009-02-13 2014-10-28 Tarsus Medical Inc. Methods and devices for treating hallux valgus
US8277459B2 (en) * 2009-09-25 2012-10-02 Tarsus Medical Inc. Methods and devices for treating a structural bone and joint deformity
US8652141B2 (en) 2010-01-21 2014-02-18 Tarsus Medical Inc. Methods and devices for treating hallux valgus
US20130116333A1 (en) * 2010-05-05 2013-05-09 Ratiopharm Gmbh Solid tapentadol in non-crystalline form
US8696719B2 (en) 2010-06-03 2014-04-15 Tarsus Medical Inc. Methods and devices for treating hallux valgus
AU2011273907B2 (en) * 2010-06-30 2015-03-19 Grunenthal Gmbh Tapentadol for use in the treatment of Irritable Bowel Syndrome
DK3656765T3 (da) * 2010-07-23 2021-06-14 Gruenenthal Gmbh Salte eller co-krystaller af 3-(3-dimethylamin-1-ethyl-2-methyl-propyl)-phenol
CN101948397A (zh) * 2010-09-07 2011-01-19 天津泰普药品科技发展有限公司 镇痛药他喷他多重要中间体的制备方法
BR112013022556A8 (pt) 2011-03-04 2018-01-16 Gruenenthal Gmbh composição farmacêutica aquosa semissólida contendo tapentadol, seu uso e uso de tapentadol
EP2680833B1 (en) * 2011-03-04 2016-03-02 Grünenthal GmbH Parenteral administration of tapentadol
LT3287123T (lt) 2011-03-04 2020-06-10 Grünenthal GmbH Vandeninė farmacinė tapentadolio kompozicija, skirta gerti
PT2694049T (pt) 2011-04-05 2019-02-06 Gruenenthal Gmbh Tapentadol para prevenir a cronicidade da dor
WO2012136351A1 (en) * 2011-04-05 2012-10-11 Grünenthal GmbH Tapentadol for treating pain associated with trigeminal neuralgia
ES2646363T3 (es) 2011-04-29 2017-12-13 Grünenthal GmbH Tapentadol para la prevención y el tratamiento de la depresión y la ansiedad
PL2968182T3 (pl) * 2013-03-15 2018-10-31 SpecGx, LLC Zniechęcająca do nadużywania stała postać dawkowania dla natychmiastowego uwalniania z funkcjonalnym rowkiem
EP2845625A1 (en) * 2013-09-04 2015-03-11 Grünenthal GmbH Tapentadol for use in the treatment of fibromyalgia and chronic fatigue syndrome
EA036258B1 (ru) 2015-03-27 2020-10-20 Грюненталь Гмбх Стабильный препарат для парентерального введения тапентадола
PT3302454T (pt) * 2015-05-26 2021-04-01 Technophage Investig E Desenvolvimento Em Biotecnologia Sa Composições para utilização no tratamento da doença de parkinson e distúrbios associados
CN109069483A (zh) 2016-02-29 2018-12-21 格吕伦塔尔有限公司 西博帕多的滴定
WO2018055070A1 (en) 2016-09-23 2018-03-29 Grünenthal GmbH Stable formulation for parenteral administration of tapentadol
ES3010208T3 (en) 2020-03-16 2025-04-01 Gruenenthal Gmbh Scored tablet comprising tapentadol
CN117042738A (zh) * 2021-03-17 2023-11-10 埃科特莱茵药品有限公司 药物剂量系统
WO2022234076A1 (en) * 2021-05-07 2022-11-10 Grünenthal GmbH Tapentadol for treating neuropathic pain in covid-19 patients

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4612008A (en) 1983-05-11 1986-09-16 Alza Corporation Osmotic device with dual thermodynamic activity
US4783337A (en) 1983-05-11 1988-11-08 Alza Corporation Osmotic system comprising plurality of members for dispensing drug
US4765989A (en) 1983-05-11 1988-08-23 Alza Corporation Osmotic device for administering certain drugs
JPS6327805A (ja) 1986-07-21 1988-02-05 Sumitomo Electric Ind Ltd 光フアイバの接続用部材及びそれを用いた接続方法
DE4426245A1 (de) * 1994-07-23 1996-02-22 Gruenenthal Gmbh 1-Phenyl-3-dimethylamino-propanverbindungen mit pharmakologischer Wirkung
US6339105B1 (en) * 1999-10-12 2002-01-15 Ortho-Mcneil Pharmaceutical, Inc. Analgesic regimen
PE20030527A1 (es) * 2001-10-24 2003-07-26 Gruenenthal Chemie Formulacion farmaceutica con liberacion retardada que contiene 3-(3-dimetilamino-1-etil-2-metil-propil) fenol o una sal farmaceuticamente aceptable del mismo y tabletas para administracion oral que la contienen
EP1572167B1 (en) 2002-12-13 2008-07-09 Euro-Celtique S.A. Transdermal buprenorphine dosage regimen for analgesia
US7413749B2 (en) 2003-03-11 2008-08-19 Purdue Pharma L.P. Titration dosing regimen for controlled release tramadol
DE102007019417A1 (de) * 2007-04-23 2008-11-13 Grünenthal GmbH Tapentadol zur Schmerzbehandlung bei Arthrose
EP1985292A1 (en) * 2007-04-23 2008-10-29 Grünenthal GmbH Titration of tapentadol

Also Published As

Publication number Publication date
PL2148670T3 (pl) 2012-04-30
ATE534378T1 (de) 2011-12-15
CA2683786A1 (en) 2008-10-30
CN101730530A (zh) 2010-06-09
WO2008128740A1 (en) 2008-10-30
CN101730530B (zh) 2013-10-23
MX2009011444A (es) 2009-11-05
RU2472497C2 (ru) 2013-01-20
JP2018030864A (ja) 2018-03-01
RU2009142940A (ru) 2011-05-27
US20090012180A1 (en) 2009-01-08
KR20180004839A (ko) 2018-01-12
EP1985292A1 (en) 2008-10-29
US20170079938A1 (en) 2017-03-23
EP3143993A1 (en) 2017-03-22
IL201479A (en) 2016-04-21
DK2148670T3 (da) 2012-03-12
KR20150027840A (ko) 2015-03-12
HK1140940A1 (en) 2010-10-29
WO2008128740A8 (en) 2010-06-17
EP2422778A1 (en) 2012-02-29
EP2148670A1 (en) 2010-02-03
HRP20120147T1 (hr) 2012-03-31
EP3603630A1 (en) 2020-02-05
IL201479A0 (en) 2010-05-31
AU2008241013B2 (en) 2013-06-20
ES2378255T3 (es) 2012-04-10
EP2148670B1 (en) 2011-11-23
CY1112320T1 (el) 2015-12-09
US11344512B2 (en) 2022-05-31
US20190290603A1 (en) 2019-09-26
ZA200907355B (en) 2010-08-25
KR20100017267A (ko) 2010-02-16
KR102078999B1 (ko) 2020-02-19
NZ580415A (en) 2012-04-27
JP2019131598A (ja) 2019-08-08
AU2008241013A1 (en) 2008-10-30
JP5933176B2 (ja) 2016-06-08
PT2148670E (pt) 2012-01-24
JP2016128468A (ja) 2016-07-14
US20160074342A1 (en) 2016-03-17
JP2010531296A (ja) 2010-09-24
SI2148670T1 (sl) 2012-03-30

Similar Documents

Publication Publication Date Title
CA2683786C (en) Use of tapentadol in the treatment of pain and with a reduced incidence of tapentadol-induced side-effects
WO2007012022A3 (en) Unit dose form with ibuprofen-famotidine admixture
EP2444072A3 (en) Non-mucoadhesive film dosage forms
IL180565A0 (en) An improved stopcock for administering medicaments into the patient's body
WO2007081949A3 (en) Small-volume oral transmucosal dosage forms
WO2008010222A3 (en) Conjugates comprising a gaba- or glycine compound, pharmaceutical compositions and combinations thereof and their use in treating cns disorders
WO2006119958A3 (en) Use of flibanserin in the treatment of chronic pain
WO2010045415A3 (en) Topical nsaid compositions having sensate component
WO2008085765A3 (en) Small volume oral transmucosal dosage forms containing sufentanil for treatment of pain
WO2007146426A3 (en) Nanoshells for drug delivery
EP3150204A3 (en) Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral or non-oral antidiabetic drug
MX2010004323A (es) Formas de dosificacion oral que comprenden acetato de licarbazepina.
MY153408A (en) Novel methods
WO2009062746A3 (de) Topische arzneimittel zur antimykotischen therapie
EP3276004A3 (en) Methods for treating chronic kidney disease
NZ628513A (en) Pharmaceutical for oral delivery comprising mgbg and methods of treating disease
WO2008011426A3 (en) Methods and medicaments for administration of ibuprofen
WO2008012796A3 (en) Pharmaceutical compositions comprising ccl2 and use of same for the treatment of inflammation
WO2008075320A3 (en) Antilipidemic pharmaceutical compositions and process for preparation thereof
IL184697A (en) Diclofenac Injection Composition, Process for its Preparation and Use for Medication and Pain Relief and / or Inflammation
WO2008092219A3 (en) Pharmaceutical composition comprising tramadol and ketoprofen
WO2007056236A3 (en) Methods of treating cancer with lipid-based platinum compound formulations administered intravenously
MY164112A (en) A combination composition comprising ibuprofen and paracetamol
IL218069A (en) Oligoscride compounds, drug, pharmaceutical, and compound for its use in therapy
WO2010075444A3 (en) Nasal formulations of metoclopramide

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20130402